• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

COVID-19 has changed surgical preferences


A new report has found that glaucoma specialists’ procedure of choice has changed as a result of the COVID-19 pandemic.

Glaucoma specialists’ procedure of choice has changed as a result of the COVID-19 pandemic, according to the lead author of a recent report in the British Journal of Ophthalmology.1

Lee Joseph Holland, a fellow in the Glaucoma Unit, Manchester Royal Eye Hospital, Manchester, UK, reported that while trabeculectomy remains the preferred procedure, surgeons have begun using alternative treatments because of the need for fewer postoperative visits.

Holland and colleagues senta cross-sectional online survey to all consultant glaucoma specialists in UK and Eire Glaucoma Society contact list to determine their practice preferences.

The participants responded to specific questions about their glaucoma surgical practices and how those preferences did or did not change as a result of the COVID-19 pandemic.

Seventy glaucoma specialists completed the survey, and the results indicated that trabeculectomy was by far the procedure of choice for 87% of surgeons.

Before the pandemic, 51 (73%) respondents reported performing minimally invasive glaucoma surgery procedures, the most frequent of which were implantation of the iStent inject (Glaukos) (51%), XEN 45 (Allergan) (36%), and the Preserflo Microshunt (Santen) (17%).

The questionnaire showed that 43 (61%) surgeons changed their glaucoma surgery practice in response to the pandemic, specifically, 21 (43%) surgeons decreased the number of trabeculectomies they performed; the alternative procedure used was diode laser (both micropulse and conventional trans-scleral cyclodiode), Holland reported.

Other alternatives included the use of glaucoma drainage devices, deep sclerectomy, and implantation of the Preserflo Microshunt.

The reason that surgeons cited for performing alternatives to trabeculectomy was the desire for fewer postoperative visits and procedures required.


1. Holland LJ, Kirwan JF, Mercieca KJ. Effect of COVID-19 pandemic on glaucoma surgical practices in the UK. Br J Ophthalmol. http://dx.doi.org/10.1136/bjophthalmol-2021-319062

Related Videos
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
Lorraine Provencher, MD, presenting slides
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Dr. SriniVas Sadda Discusses Vision for ARVO as New President: Collaboration, Funding Challenges, and Impact of Annual Meetings
Deb Ristvedt, DO's CIME 2024 Talk Highlights Innovations in Treating Glaucoma via the Trabecular Meshwork
Dr. Inder Paul Singh's Insights: Improving Glaucoma Outcomes with Early Intervention and Reduced Medication
CIME 2024: Neda Shamie, MD, reports on a morning session packed with refractive surgery options, retina, glaucoma, and a 'mite-y' Demodex discussion
Highlights from the 18th Annual Controversies in Modern Eye Care Symposium: Arjan Hura, MD, on Refractive Surgery, Retina Care, and Record Attendance
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
© 2024 MJH Life Sciences

All rights reserved.